source
- STAT+: Biotech raises $42 million to run Huntington’s disease trialLatus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.STAT · 2mo ago↗ source
- UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesThe buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.BioPharma Dive · 2mo ago↗ source
- What is your AI drug repurposing strategy missing?Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.BioPharma Dive · 2mo ago↗ source